OrthoPediatrics Corp. (NASDAQ:KIDS) Stock Has Consensus Price Target of $26.44

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have received a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $26.44.

Several equities research analysts recently commented on the company. TD Cowen reaffirmed a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Needham & Company LLC boosted their target price on OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. BTIG Research reissued a “buy” rating and issued a $29.00 target price on shares of OrthoPediatrics in a research report on Monday, September 14th. Piper Sandler restated an “overweight” rating and set a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Finally, Weiss Ratings raised shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th.

Insider Buying and Selling

In other news, major shareholder Squadron Capital Llc sold 302,369 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the transaction, the insider directly owned 6,201,764 shares of the company’s stock, valued at $130,299,061.64. This represents a 4.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director David R. Pelizzon sold 302,369 shares of the stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $21.01, for a total value of $6,352,772.69. Following the transaction, the director directly owned 6,201,764 shares in the company, valued at $130,299,061.64. The trade was a 4.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 2,100,000 shares of company stock worth $46,747,931. 32.50% of the stock is owned by insiders.

Institutional Trading of OrthoPediatrics

Hedge funds have recently bought and sold shares of the company. Squarepoint Ops LLC increased its position in shares of OrthoPediatrics by 95.0% during the 2nd quarter. Squarepoint Ops LLC now owns 195,468 shares of the company’s stock valued at $3,739,000 after purchasing an additional 95,230 shares during the last quarter. Waverly Advisors LLC lifted its stake in shares of OrthoPediatrics by 6.7% in the 2nd quarter. Waverly Advisors LLC now owns 12,366 shares of the company’s stock worth $237,000 after purchasing an additional 775 shares during the period. Nantahala Capital Management LLC purchased a new position in shares of OrthoPediatrics in the second quarter worth approximately $4,636,002. Grandeur Peak Global Advisors LLC bought a new stake in OrthoPediatrics during the second quarter valued at approximately $954,000. Finally, Bank of America Corp DE bought a new stake in OrthoPediatrics during the second quarter valued at approximately $268,000. Hedge funds and other institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Price Performance

Shares of NASDAQ KIDS opened at $22.55 on Friday. OrthoPediatrics has a twelve month low of $14.42 and a twelve month high of $26.74. The firm has a market cap of $588.78 million, a P/E ratio of -13.42 and a beta of 0.99. The company has a 50 day moving average of $22.52 and a 200 day moving average of $19.37. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04. The business had revenue of $70.51 million for the quarter, compared to analysts’ expectations of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. As a group, research analysts expect that OrthoPediatrics will post -1.14 EPS for the current fiscal year.

About OrthoPediatrics

OrthoPediatrics Corp. (NASDAQ: KIDS) develops, manufactures and sells orthopedic products designed specifically for children. The company focuses on addressing the distinct anatomical and clinical needs of pediatric patients, offering implants, instruments and related technologies for orthopedic surgery.

Its product portfolio includes solutions for pediatric trauma and deformity correction, scoliosis and spinal disorders, sports medicine, limb lengthening and reconstruction, and neuromuscular conditions.